City Therapeutics announced the first participant has been dosed in its Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease. The trial is a first-in-human study evaluating the safety, tolerability, and pharmacodynamics of the RNAi therapeutic candidate, with initial data expected in mid-2027.
City Therapeutics Insider ARCH Venture Partners XII LLC Buys $3.06M of Stock
ARCH Venture Partners XII LLC bought 170,000 shares of City Therapeutics, Inc. at $18.00 a share, worth $3.06M in total on Oct 19, 2026. Shares held after the trade: 13,692,507 (+1.3%).
City Therapeutics Insider Robert Nelsen Buys $3.06M of Stock
Robert Nelsen bought 170,000 shares of City Therapeutics, Inc. at $18.00 a share, worth $3.06M in total on Oct 19, 2026. Shares held after the trade: 13,692,507 (+1.3%).
City Therapeutics filed its amended and restated certificate of incorporation and bylaws in connection with the completion of its initial public offering. The amendments authorize 500 million shares of common stock and 10 million shares of undesignated preferred stock while eliminating stockholder action by written consent. These administrative changes are standard corporate governance updates triggered by the company's transition to a public entity.